129 related articles for article (PubMed ID: 2103961)
21. [Relation of the soluble cytoadhesion molecules VCAM-1 and ICAM-1 to selected clinical and laboratory indicators in multiple myeloma].
Scudla V; Budíková M; Bacovský J; Ordeltová M; Opíchalová D; Heincová V
Vnitr Lek; 1999 Oct; 45(10):583-90. PubMed ID: 10951865
[TBL] [Abstract][Full Text] [Related]
22. [Multiple myeloma with 5-year survival. Study of initial prognostic factors. Role of beta-2-microglobulin].
Franco M; Fuzibet JG; Cassuto JP; Pesce A; Ziegler G; Dujardin P
Rev Rhum Mal Osteoartic; 1985 Nov; 52(11):619-23. PubMed ID: 3909365
[TBL] [Abstract][Full Text] [Related]
23. Immunologic markers of AIDS progression: consistency across five HIV-infected cohorts. Multicohort Analysis Project Workshop. Part I.
AIDS; 1994 Jul; 8(7):911-21. PubMed ID: 7946100
[TBL] [Abstract][Full Text] [Related]
24. Circadian variations of interleukin-2 receptors, serum thymidine kinase and beta-2-microglobulin in patients with non-Hodgkin's lymphoma and normal controls.
Micke O; Schäfer U; Wörmann B; Hiddemann W; Willich N
Anticancer Res; 1997; 17(4B):3007-10. PubMed ID: 9329587
[TBL] [Abstract][Full Text] [Related]
25. [Soluble interleukin-6 receptors in the serum in multiple myeloma].
Scudla V; Kubalová D; Bacovský J; Lukes J; Vavrdová V
Cas Lek Cesk; 1996 Nov; 135(22):719-22. PubMed ID: 8998823
[TBL] [Abstract][Full Text] [Related]
26. Beta-2-microglobulin is superior to N-acetyl-beta-glucosaminidase in predicting prognosis in idiopathic membranous nephropathy.
Hofstra JM; Deegens JK; Willems HL; Wetzels JF
Nephrol Dial Transplant; 2008 Aug; 23(8):2546-51. PubMed ID: 18308774
[TBL] [Abstract][Full Text] [Related]
27. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
[TBL] [Abstract][Full Text] [Related]
28. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.
Kyrtsonis MC; Vassilakopoulos TP; Siakantaris MP; Kokoris SI; Gribabis DA; Dimopoulou MN; Angelopoulou MK; Pangalis GA
Eur J Haematol; 2004 Apr; 72(4):252-8. PubMed ID: 15089762
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of telomerase activity in multiple myeloma.
Shiratsuchi M; Muta K; Abe Y; Motomura S; Taguchi F; Takatsuki H; Uike N; Umemura T; Nawata H; Nishimura J
Cancer; 2002 Apr; 94(8):2232-8. PubMed ID: 12001122
[TBL] [Abstract][Full Text] [Related]
30. [Expression and clinical significance of beta-catenin in multiple myeloma].
Li J; Zhang DB; Luo SK; Zhao Y; Huang BH; Gu JL
Ai Zheng; 2007 Sep; 26(9):1010-4. PubMed ID: 17927863
[TBL] [Abstract][Full Text] [Related]
31. Interleukins, TNF-alpha and beta-2M in patients with B cell chronic lymphocytic leukemia.
Mavridis AK; Tsiara S; Makis A; Chaidos A; Christou L; Seferiadis K; Bourantas KL
J Exp Clin Cancer Res; 1998 Dec; 17(4):445-8. PubMed ID: 10089066
[TBL] [Abstract][Full Text] [Related]
32. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma.
Hallek M; Wanders L; Ostwald M; Busch R; Senekowitsch R; Stern S; Schick HD; Kuhn-Hallek I; Emmerich B
Leuk Lymphoma; 1996 Aug; 22(5-6):439-47. PubMed ID: 8882957
[TBL] [Abstract][Full Text] [Related]
33. GM-CSF raises serum levels of beta 2-microglobulin and thymidine kinase in patients with chronic lymphocytic leukaemia.
Itälä M; Pelliniemi TT; Remes K
Br J Haematol; 1996 Jul; 94(1):129-32. PubMed ID: 8757522
[TBL] [Abstract][Full Text] [Related]
34. Serum thymidine kinase in monoclonal gammopathies. A prospective study. The Cooperative Group for Study and Treatment of Multiple Myeloma.
Luoni R; Ucci G; Riccardi A; Gobbi P; Avato FM; Vignale C; Ascari E
Cancer; 1992 Mar; 69(6):1368-72. PubMed ID: 1540874
[TBL] [Abstract][Full Text] [Related]
35. High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment.
Urbańska-Ryś H; Robak T
Mediators Inflamm; 2003 Aug; 12(4):229-35. PubMed ID: 14514474
[TBL] [Abstract][Full Text] [Related]
36. [Significance of serum levels of beta-2-microglobulin in dialysis patients].
Baldrati L; Baldrati L; Delvecchio C; Capponcini C; Docci D; Turci F; Feletti C
Recenti Prog Med; 1990 Sep; 81(9):561-3. PubMed ID: 2263750
[TBL] [Abstract][Full Text] [Related]
37. [Prognostic value of serum beta2-microglobulin in multiple myeloma].
Bettini R; Redaelli S; Maino C; Bertuol S; Costantini C; Lazzarini A; Brivio L; Gorini M
Recenti Prog Med; 2005 Feb; 96(2):81-6. PubMed ID: 15844767
[TBL] [Abstract][Full Text] [Related]
38. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance.
Leleu X; Le Friec G; Facon T; Amiot L; Fauchet R; Hennache B; Coiteux V; Yakoub-Agha I; Dubucquoi S; Avet-Loiseau H; Mathiot C; Bataille R; Mary JY;
Clin Cancer Res; 2005 Oct; 11(20):7297-303. PubMed ID: 16243800
[TBL] [Abstract][Full Text] [Related]
39. [Beta 2 microglobulin in some hematologic neoplasms].
Rodríguez MA; Lira P; Foradori A; Grebe G
Rev Med Chil; 1989 Jun; 116(6):538-42. PubMed ID: 2664940
[TBL] [Abstract][Full Text] [Related]
40. [The prognosis of patients with multiple myeloma--the aspect of histological distribution to the renal tissue and serum level of beta 2-MG].
Inoue Y; Suzuki K; Enomoto H; Takemura T; Nakamura K
Rinsho Ketsueki; 1992 Aug; 33(8):1012-6. PubMed ID: 1404855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
